A nurse is providing teaching to a client who is receiving intermittent parenteral metronidazole. Which of the following conditions should the nurse recognize as an indication for this medication?

A. Bruxism: Bruxism, or teeth grinding, is a potential adverse effect of citalopram but is generally less severe than confusion. While it should be monitored and reported if severe or persistent, it is not typically considered a priority adverse effect.
B. Confusion: Confusion can indicate a serious adverse reaction or complication, such as serotonin syndrome, which is a potentially life-threatening condition associated with the use of selective serotonin reuptake inhibitors (SSRIs) like citalopram. Therefore, confusion is the priority adverse effect to report to the provider.
C. Insomnia: Insomnia is a common side effect of citalopram and other SSRIs but is generally less severe than confusion. It should be monitored and reported if severe or persistent, but it is not typically considered a priority adverse effect.
D. Weight loss: Weight loss can occur as a side effect of citalopram but is generally less severe than confusion. It should be monitored and reported if excessive or rapid, but it is not typically considered a priority adverse effect.

A. Insomnia: Pioglitazone is not typically associated with insomnia as an adverse effect.

Insomnia is more commonly associated with stimulant medications or certain medical conditions.
B. Fluid retention: Pioglitazone, a thiazolidinedione, can cause fluid retention as an adverse effect. This can lead to peripheral edema and exacerbation of heart failure, particularly in

susceptible individuals. Monitoring for signs and symptoms of fluid retention, such as peripheral edema and weight gain, is essential.
C. Tinnitus: Tinnitus is not a commonly reported adverse effect of pioglitazone. Tinnitus is more commonly associated with medications such as certain antibiotics, NSAIDs, and ototoxic drugs.
D. Orthostatic hypotension: Orthostatic hypotension is not typically associated with pioglitazone.

It is more commonly associated with medications that affect blood pressure regulation, such as antihypertensives and alpha-blockers.